After taking expert advice from world class toxicology and DMPK experts, OncoTherics has commenced an innovative DMPK equivalence programme. The close chemical relationship between OCT1002 …
Read more
OncoTherics completes CMC scale up development
GMP scale up development has been completed for OCT1002 and OCT1004. The synthesis route has been re-designed for both assets to ensure ready supply of …
Read more
OncoTherics Poland SA AGM 2023
OncoTherics second annual general meeting was held on 30th June 2023 and the FY2022 audited accounts were approved. The company looks forward to progressing its …
Read more
OncoTherics Poland SA first AGM
OncoTherics held its first AGM as a SPOŁKA AKCYJNA on 29th June 2022 in Warsaw, Poland. The Auditors report was presented alongside the 2021 consolidated …
Read more
Hypoxia-modifier reports encouraging tolerability
ITPP (Myo-lnositol trispyrophosphate) is a natural phosphosugar derivative – well known for its ability to trigger the dissociation of molecular oxygen from haemoglobin. Experimental studies …
Read more
OncoTherics secures 2.32M PLN in private funding
OncoTherics has successfully raised 2.32M PLN in first round funding from founders and Polish investors to leverage 5M PLN of Polish regional grant funding. The …
Read more
New Hypoxia probe reviewed in multicellular tumour spheroid cultures (MCTSs)
The link below connects to a new paper which reviews a novel hypoxia marker – HypoxiTRAK™ – a homogeneous live-cell permeant reagent which provides a …
Read more
OncoTherics Poland S.A.
OncoTherics Poland has today successfully transformed from a Spółka z ograniczoną odpowiedzialnością (Sp. z o.o) to a Spółka akcyjna (S.A.) company as part of a …
Read more
OncoTherics presenting at #GPWInnovationDay 13th October 2021
OncoTherics CEO, Stefan Ogrodzinski, is due to showcase OncoTherics’ novel drug technology at the upcoming GPWInnovation day, sponsored by Trigon. The online conference aims to …
Read more
Hypoxia signaling – Challenges and opportunities for cancer therapy
This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact. Click …
Read more